← Leaderboards
Mitchell Ho
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesMalignant NeoplasmsPhage DisplayTechnologyCancer TherapyTherapeutic AntibodiesMesothelinCellsPublishingAntibody EngineeringSiteCell SurfaceSignal TransductionNanobodiesBindingBaseTumorNational Cancer InstituteGpc3 GeneMalignant Neoplasm Of LiverMesotheliomaProteinsLibrariesGlypican
Grant awards (29)
Development of antibody engineering-based cancer therapies$2,142,050
ZIA · FY2025 · CA · contact PI
Antibody Engineering Program$918,022
ZIC · FY2025 · CA · contact PI
Development of antibody engineering-based cancer therapies$1,761,905
ZIA · FY2024 · CA · contact PI
Antibody Engineering Program$755,102
ZIC · FY2024 · CA · contact PI
Development of antibody engineering-based cancer therapies$1,851,352
ZIA · FY2023 · CA · contact PI
Antibody Engineering Program$502,510
ZIC · FY2023 · CA · contact PI
Development of neutralizing nanobodies against SARS-CoV-2$290,927
ZIA · FY2023 · CA · contact PI
Development of new antibody-based cancer therapies$1,629,751
ZIA · FY2022 · CA · contact PI
Antibody Engineering Program$588,522
ZIC · FY2022 · CA · contact PI
Development of neutralizing nanobodies against SARS-CoV-2$45,270
ZIA · FY2022 · CA · contact PI
Development of new antibody-based cancer therapies$1,541,067
ZIA · FY2021 · CA · contact PI
Antibody Engineering Program$638,442
ZIC · FY2021 · CA · contact PI
Development of neutralizing nanobodies against SARS-CoV-2$22,016
ZIA · FY2021 · CA · contact PI
Development of new antibody-based cancer therapies$1,081,995
ZIA · FY2020 · CA · contact PI
Antibody Engineering Program$582,613
ZIC · FY2020 · CA · contact PI
Development of neutralizing nanobodies against SARS-CoV-2$416,151
ZIA · FY2020 · CA · contact PI
Development of new antibody-based cancer therapies$1,340,134
ZIA · FY2019 · CA · contact PI
Antibody Engineering Program$470,858
ZIC · FY2019 · CA · contact PI
Development of new antibody-based cancer therapies$1,849,077
ZIA · FY2018 · CA · contact PI
Development of new antibody-based cancer therapies$1,311,816
ZIA · FY2017 · CA · contact PI
Development of new antibody-based cancer therapies$1,192,823
ZIA · FY2016 · CA · contact PI
Development of antibody-based cancer therapies$1,073,044
ZIA · FY2015 · CA · contact PI
Development of antibody-based cancer therapies$1,100,911
ZIA · FY2014 · CA · contact PI
Antibody Therapy of Cancer$908,022
ZIA · FY2013 · CA · contact PI
Antibody Therapy of Cancer$735,484
ZIA · FY2012 · CA · contact PI
Antibody Therapy of Cancer$747,016
ZIA · FY2011 · CA · contact PI
Antibody Therapy of Cancer$464,972
ZIA · FY2010 · CA · contact PI
Antibody Therapy of Cancer$661,164
ZIA · FY2009 · CA · contact PI
Antibody Therapy of Cancer$55,533
Z01 · FY2008 · CA · contact PI